Biointelect Pty, Ltd.
Biointelect is a leading strategic planning and commercialisation advisory firm for the life science sector based in Australia. Founded in 2012, it channels the vision of its co-founders Jennifer and Karl Herz to bring innovative science to market. The company offers bespoke consulting services and strategic insights across the entire life science ecosystem to accelerate healthcare innovation for patients. With a global perspective and extensive experience in biotechnology and pharmaceutical sectors, Biointelect helps clients develop and execute strategies for new therapies, navigate regulatory pathways, and achieve successful market entry.
Industries
Nr. of Employees
small (1-50)
Biointelect Pty, Ltd.
Level 4, 143 Macquarie Street, Sydney NSW Australia 2000
Products
Virtual incubator for vaccine and infectious disease innovations (Venturer)
A nation-wide virtual incubator designed to support SME-led early-stage vaccine, vaccine-related and infectious disease immunotherapy innovations to become investment-ready and commercialised locally.
Virtual incubator for vaccine and infectious disease innovations (Venturer)
A nation-wide virtual incubator designed to support SME-led early-stage vaccine, vaccine-related and infectious disease immunotherapy innovations to become investment-ready and commercialised locally.
Services
Consulting for R&D roadmaps, target product profiles, portfolio prioritisation, market analysis and grant/business case preparation.
Protocol design, trial execution support, site start-up and full-service clinical research capabilities in partnership with clinical operations providers.
Regulatory classification, gap analysis, submission roadmaps and preparation for regulator engagement across jurisdictions.
Go-to-market strategy, partner identification, pricing and lifecycle management to prepare products for launch and scale.
HTA preparation, reimbursement strategy, economic assessments and pricing strategy to support funded access.
Policy development, white papers, stakeholder workshops and public sector engagement to shape health system frameworks.
Consulting for R&D roadmaps, target product profiles, portfolio prioritisation, market analysis and grant/business case preparation.
Protocol design, trial execution support, site start-up and full-service clinical research capabilities in partnership with clinical operations providers.
Regulatory classification, gap analysis, submission roadmaps and preparation for regulator engagement across jurisdictions.
Go-to-market strategy, partner identification, pricing and lifecycle management to prepare products for launch and scale.
HTA preparation, reimbursement strategy, economic assessments and pricing strategy to support funded access.
Policy development, white papers, stakeholder workshops and public sector engagement to shape health system frameworks.
Expertise Areas
- Commercialisation strategy
- Clinical trial management and operations
- Regulatory strategy and submissions
- Market access, HTA and health economics
Key Technologies
- Viral vector manufacturing
- Cell and gene therapy manufacturing
- Vaccine development
- Nanoparticle drug delivery
News & Updates
Biointelect received a $32.9 million grant from the Australian Government’s Medical Research Future Fund (MRFF) to support early-stage Australian companies in vaccine and immune-related therapies, establishing a virtual incubator called Biointelect Venturer.
Biointelect played a key role in the conceptualisation, planning, and operationalisation of the NSW Viral Vector Manufacturing Facility, a GMP-grade facility to support viral vector production for gene therapy and vaccines.
Biointelect convened Australia's first Vaccine Value Chain Conference in May 2024, bringing stakeholders together to improve vaccine development, translation, and access, resulting in an outcomes paper with strategic recommendations.
Biointelect and CR2O have formed a strategic partnership to deliver integrated clinical trial capabilities and product development consultancy across Australia, Europe, and the US, enhancing the full innovation journey from pre-clinical to market.
Biointelect discusses reforming Australia's evaluation and funding of medicines and vaccines to improve access and innovation, supported by a whitepaper.
Biointelect received a significant grant to establish a virtual incubator supporting vaccine and immune therapy research in Australia.
Biointelect received a $32.9 million grant from the Australian Government’s Medical Research Future Fund (MRFF) to support early-stage Australian companies in vaccine and immune-related therapies, establishing a virtual incubator called Biointelect Venturer.
Biointelect played a key role in the conceptualisation, planning, and operationalisation of the NSW Viral Vector Manufacturing Facility, a GMP-grade facility to support viral vector production for gene therapy and vaccines.
Biointelect convened Australia's first Vaccine Value Chain Conference in May 2024, bringing stakeholders together to improve vaccine development, translation, and access, resulting in an outcomes paper with strategic recommendations.
Biointelect and CR2O have formed a strategic partnership to deliver integrated clinical trial capabilities and product development consultancy across Australia, Europe, and the US, enhancing the full innovation journey from pre-clinical to market.
Biointelect discusses reforming Australia's evaluation and funding of medicines and vaccines to improve access and innovation, supported by a whitepaper.
Biointelect received a significant grant to establish a virtual incubator supporting vaccine and immune therapy research in Australia.